retatrutide weight loss clinical trial results Lilly's triple agonist achieves 16.8% in phase 3 Retatrutide shows 30% weight loss

The increased number of women of reproductive age taking GLP-1-based therapeutics, along with the potentially unexpected restart of fertility, might indicate that an increasing number of infants will be exposed to GLP-1 agonists prenatally

Also, the inclusion of the drugs in public drug formularies and expanded insurance coverage for chronic condition management escalates accessibility, especially for underserved populations, and is driving the demand and growth of the market

It is extensively utilized to investigate the pathophysiology of MS and to assess potential new treatments [261]

Benjamini-Hochberg corrected P ( c - g ) Data represents mean SEM